Adcetris Review Gives ODAC Chance To Apply Principles On Accelerated Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
BLAs for Seattle Genetics' antibody-drug conjugate to treat two rare lymphomas are based on single-arm trials, and the company has begun a confirmatory study for only one indication.